PTGX
Protagonist Therapeutics Inc
NASDAQ: PTGX · HEALTHCARE · BIOTECHNOLOGY
$103.50
-5.26% today
Updated 2026-06-05
Market cap
$6.10B
P/E ratio
—
P/S ratio
85.51x
EPS (TTM)
$-1.81
Dividend yield
—
52W range
$49 – $108
Volume
0.6M
Protagonist Therapeutics Inc (PTGX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+3.5%
Last 4 quarters
Revenue YoY growth
+99.0%
Most recent quarter
EPS YoY growth
+126.3%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.6%
Last 4 reports
Positive reaction rate
75%
3 of 4 quarters
Largest single-day move
-5.5%
2025-08-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-05-05 | $0.05 | +109.9% | $99.52 | $103.97 | +4.5% |
| 2026-02-25 | $-0.69 | -102.8% | $87.39 | $88.39 | +1.1% |
| 2025-11-06 | $-0.62 | +1.6% | $77.88 | $79.54 | +2.1% |
| 2025-08-06 | $-0.55 | +5.2% | $53.90 | $50.96 | -5.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $-0.50 | $0.05 | +109.9% | $56.37M | +99.0% |
| 2025-12-31 | $-0.34 | $-0.69 | -102.8% | $7.44M | -95.6% |
| 2025-09-30 | $-0.63 | $-0.62 | +1.6% | $4.71M | +0.8% |
| 2025-06-30 | $-0.58 | $-0.55 | +5.2% | $5.55M | +33.1% |
| 2025-03-31 | $0.11 | $-0.19 | -272.7% | $28.32M | -88.9% |
| 2024-12-31 | $0.25 | $1.98 | +692.0% | $170.64M | +184.4% |
| 2024-09-30 | $-0.60 | $-0.54 | +10.0% | $4.67M | — |
| 2024-06-30 | $-0.60 | $-0.50 | +16.7% | $4.17M | — |
| 2024-03-31 | $1.19 | $3.26 | +173.9% | $254.95M | — |
| 2023-12-31 | $-0.03 | $0.44 | +1566.7% | $60.00M | — |
| 2023-09-30 | $-0.69 | $-0.58 | +15.9% | — | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $4.20 | $0.5B | +1030.0% | 16 | medium |
| 2027 (E) | $-0.80 | $0.2B | +-64.4% | 16 | low |
| 2028 (E) | $1.10 | $0.3B | +72.9% | 16 | medium |
| 2029 (E) | $2.40 | $0.5B | +50.0% | 16 | medium |
| 2030 (E) | $3.80 | $0.6B | +29.2% | 16 | low |
Frequently asked questions
Has Protagonist Therapeutics Inc beaten earnings estimates?
Protagonist Therapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, averaging a +3.5% surprise over the last 4. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.
How does PTGX stock react to earnings?
PTGX has moved an average of +0.6% the day after earnings over its last 4 reports, finishing higher after 3 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.
What is Protagonist Therapeutics Inc's revenue growth rate?
Protagonist Therapeutics Inc reported year-over-year revenue growth of +99.0% in its most recent quarter, with EPS up +126.3%. EPS outpacing revenue is operating leverage at work, meaning profit is compounding faster than sales.
What is the expected EPS for PTGX next fiscal year?
Analysts expect Protagonist Therapeutics Inc to earn about $4.20 per share next fiscal year, on revenue of $520.00M, from 16 analysts. Forward estimates matter because today's price is justified by future earnings, not trailing ones.
What are PTGX's longer-term earnings estimates?
Consensus sees EPS reaching about $3.80 by 2030, on roughly $620.00M of revenue. Longer-dated estimates carry lower confidence but frame the growth runway the current valuation leans on.